Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 16/20 | 0.72 |
| ▸ | JAK2 | O60674 | 2/20 | 0.56 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.56 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.56 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.56 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.56 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.56 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3117593 | 1.00 | MET (0.72) | METJAK2MAP4K2MAP3K1AAK1 | |
| SCHEMBL16125996 | 0.95 | MET (0.71) | METJAK2MAP4K2MAP3K1AAK1 | |
| SCHEMBL3114941 | 0.90 | MET (0.78) | METJAK2MAP4K2MAP3K1AAK1 | |
| SCHEMBL487718 | 0.90 | MET (0.78) | METJAK2MAP4K2MAP3K1AAK1 | |
| SCHEMBL30452512 | 0.90 | MET (0.78) | METJAK2MAP4K2MAP3K1AAK1 | |
| SCHEMBL30454037 | 0.90 | MET (0.85) | METJAK2ALK | |
| SCHEMBL488459 | 0.90 | MET (0.85) | METJAK2ALK | |
| SCHEMBL3110705 | 0.89 | MET (0.58) | METJAK2MAP4K2MAP3K1AAK1 | |
| SCHEMBL10216680 | 0.89 | MET (0.76) | METJAK2MAP4K2MAP3K1AAK1 | |
| SCHEMBL488837 | 0.89 | MET (0.84) | METJAK2ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288086-A1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2014-09-25 | — | — | US | claimed |
| EP-1786785-B9 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER (US) | 2013-05-22 | — | — | EP | claimed |
| US-20120263706-A1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. | 2012-10-18 | — | — | US | claimed |
| US-20100324061-A1 | including crizotinib which is 3-[(R)-1-(2-chloro-3,6-difluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; c-met inhibitors; hepatocyte growth factor (HGF) receptor (c-MET) receptor tyrosine kinase (RTK) | AGOURON PHARMACEUTICALS, INC. | 2010-12-23 | — | — | US | claimed |
| EP-1786785-B1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER (US) | 2010-04-07 | — | — | EP | claimed |
| EP-1786785-A2 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | Pfizer, Inc. (US) | 2007-05-23 | — | — | EP | claimed |
| US-20060046991-A1 | Crizotinib, a c-Met protein kinase inhibitor anticancer agent; 3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine is crizotinib | AGOURON PHARMACEUTICALS, INC. | 2006-03-02 | — | — | US | claimed |
| WO-2006021884-A2 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2006-03-02 | — | — | WO | claimed |
| EP-2315601-B1 | COMBINATION OF A C-MET ANTAGONIST AND AN AMINOHETEROARYL COMPOUND FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2018-02-14 | — | — | EP | disclosed |
| US-9375425-B2 | Combination of a C-Met antagonist and an aminoheteroaryl compound for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2016-06-28 | — | — | US | disclosed |
| US-20150250780-A1 | COMBINATION OF A C-MET ANTAGONIST AND AN AMINOHETEROARYL COMPOUND FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2015-09-10 | — | — | US | disclosed |
| US-20140288086-A1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-8785632-B2 | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140186356-A1 | COMBINATION OF A C-MET ANTAGONIST AND AN AMINOHETEROARYL COMPOUND FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2014-07-03 | — | — | US | disclosed |
| US-7465842-B2 | Enantioselective biotransformation for preparation of protein tyrosine kinase inhibitor intermediates | AGOURON PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465842-B2 | Enantioselective biotransformation for preparation of protein tyrosine kinase inhibitor intermediates | AGOURON PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| EP-1786785-A2 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | Pfizer, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060178374-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| US-20060046991-A1 | Crizotinib, a c-Met protein kinase inhibitor anticancer agent; 3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine is crizotinib | AGOURON PHARMACEUTICALS, INC. | 2006-03-02 | — | — | US | disclosed |
| WO-2006021884-A2 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060046991-A1 | Crizotinib, a c-Met protein kinase inhibitor anticancer agent; 3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine is crizotinib | ALK, MET, ERBB2 | MET 2/4885JAK2 192/4885MAP4K2 39/4885 |
| US-20100324061-A1 | including crizotinib which is 3-[(R)-1-(2-chloro-3,6-difluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; c-met inhibitors; hepatocyte growth factor (HGF) receptor (c-MET) receptor tyrosine kinase (RTK) | MET, HGF, ALK | MET 1/4885JAK2 97/4885MAP4K2 99/4885 |
| US-20120263706-A1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | MET, MAP3K15, MAP3K1 | MET 1/4885JAK2 350/4885MAP4K2 12/4885 |
| US-20150250780-A1 | COMBINATION OF A C-MET ANTAGONIST AND AN AMINOHETEROARYL COMPOUND FOR THE TREATMENT OF CANCER | MET, HGF, EGFR | MET 1/4885JAK2 330/4885MAP4K2 1644/4885 |
| US-20060178374-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP3K15, CDC42BPA | MET 1/4885JAK2 342/4885MAP4K2 12/4885 |
| US-20140186356-A1 | COMBINATION OF A C-MET ANTAGONIST AND AN AMINOHETEROARYL COMPOUND FOR THE TREATMENT OF CANCER | MET, HGF, EGFR | MET 1/4885JAK2 330/4885MAP4K2 1644/4885 |
| US-20140288086-A1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | MET, MAP3K15, MAP3K1 | MET 1/4885JAK2 350/4885MAP4K2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.